Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 231

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 7
Chunk 231
---
 2,050 shares issuable upon vesting of RSUs that are currently vested 
                or will become vested within 60 days of March 17, 2025, all of which expire on March 8, 2033, and with no exercise price.          
---------------------------------------------------------------------------------------------------------------------------------------------------

(3)       Consists of 2,500 ordinary shares of Evogene issuable upon exercise of options that are currently exercisable or exercisable within    
        60 days of March 17, 2025, which expire on September 1, 2031. The exercise price of these options is NIS 91.7 per ordinary share. Elran  
      Haber serves as the CEO of our subsidiary company Biomica, and as such, also holds options to purchase shares of Biomica. For a description
           of our subsidiaries’ equity incentive plans, please see “Item 6. Directors, Senior Management and Employees—B. Compensation—Share     
                                             Option and Incentive Plans—Subsidiary Equity Incentive Plans”.                                      
-------------------------------------------------------------------------------------------------------------------------------------------------

(4)        Consists of 16,250 ordinary shares issuable upon exercise of options that are currently exercisable or exercisable within 60 days     
      of March 17, 2025, of which options to purchase the following number of shares expire on the following dates, respectively: 3,000 on August
         8, 2027, 750 on July 30, 2029, 7,000 on September 1, 2031, 3,000 on March 8, 2033 and 2,500 on November 20, 2034. The weighted average  
                                            exercise price of these options is NIS 81.36 per ordinary share.                                     
-------------------------------------------------------------------------------------------------------------------------------------------------

(5)        Consists of 15,500 ordinary shares issuable upon exercise of options that are currently exercisable or exercisable within 60 days     
      of March 17, 2025, of which options to purchase the following number of shares expire on the following dates, respectively: 1,000 on August
        10, 2026, 250 on August 8, 2027,250 on August 6, 2028, 250 on September 23, 2029, 250 on September 22, 2030, 3,600 on September 1, 2031, 
         3,600 on September 15,